TR201910293T4 - Nazal influenza aşısı bileşimi. - Google Patents

Nazal influenza aşısı bileşimi. Download PDF

Info

Publication number
TR201910293T4
TR201910293T4 TR2019/10293T TR201910293T TR201910293T4 TR 201910293 T4 TR201910293 T4 TR 201910293T4 TR 2019/10293 T TR2019/10293 T TR 2019/10293T TR 201910293 T TR201910293 T TR 201910293T TR 201910293 T4 TR201910293 T4 TR 201910293T4
Authority
TR
Turkey
Prior art keywords
vaccine composition
influenza vaccine
nasal influenza
nasal
adjuvant
Prior art date
Application number
TR2019/10293T
Other languages
English (en)
Inventor
Hasegawa Hideki
Suzuki Tadaki
Ainai Akira
Kamishita Taizou
Miyazaki Takashi
Original Assignee
Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Toko Yakuhin Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By Director General Of Nat Institute Of Infectious Diseases, Toko Yakuhin Kogyo Kk filed Critical Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Publication of TR201910293T4 publication Critical patent/TR201910293T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Buluş, bir adjuvan içermemesi ile karakterize edilen, karboksi vinil polimeri içeren bir jel bazlı materyal ve etkisiz hale getirilmiş bir bütün influenza viryonu içeren, nazal mukozaya püskürtme uygulamaya yönelik bir influenza aşısı bileşimi ile ilgilidir.
TR2019/10293T 2012-12-28 2013-10-23 Nazal influenza aşısı bileşimi. TR201910293T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012287900 2012-12-28

Publications (1)

Publication Number Publication Date
TR201910293T4 true TR201910293T4 (tr) 2019-07-22

Family

ID=51020588

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10293T TR201910293T4 (tr) 2012-12-28 2013-10-23 Nazal influenza aşısı bileşimi.

Country Status (27)

Country Link
US (2) US20160015800A1 (tr)
EP (2) EP2939692B1 (tr)
JP (1) JP6247639B2 (tr)
KR (1) KR102071099B1 (tr)
CN (2) CN110038123A (tr)
AU (1) AU2013367751B2 (tr)
BR (1) BR112015015523B1 (tr)
CA (1) CA2894223C (tr)
CY (1) CY1122372T1 (tr)
DK (1) DK2939692T3 (tr)
ES (1) ES2731899T3 (tr)
HK (1) HK1209646A1 (tr)
HU (1) HUE044434T2 (tr)
IL (1) IL239284B (tr)
LT (1) LT2939692T (tr)
MX (1) MX371154B (tr)
MY (1) MY173503A (tr)
NZ (1) NZ708922A (tr)
PH (1) PH12015501482B1 (tr)
PL (1) PL2939692T3 (tr)
PT (1) PT2939692T (tr)
RU (1) RU2652296C2 (tr)
SG (2) SG10201705190TA (tr)
SI (1) SI2939692T1 (tr)
TR (1) TR201910293T4 (tr)
TW (1) TWI624280B (tr)
WO (1) WO2014103488A1 (tr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114169A1 (en) * 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
KR102491446B1 (ko) * 2014-06-25 2023-01-20 도코 야쿠힌 고교 가부시키가이샤 인플루엔자 백신의 경비접종 시스템
JP6322844B2 (ja) 2014-06-25 2018-05-16 東興薬品工業株式会社 医療用シリンジに用いられる点鼻用噴霧ノズル
CN105342982B (zh) * 2015-11-19 2018-08-28 上海现代药物制剂工程研究中心有限公司 经鼻给药的流感疫苗免疫制剂及其制备方法
TW201722472A (zh) * 2015-11-27 2017-07-01 Nitto Denko Corp 口腔內投與用疫苗醫藥組合物及口腔內投與用疫苗醫藥組合物之製造方法
US20210290715A1 (en) * 2016-07-29 2021-09-23 Natural Healthcare Co., Ltd. Anti-influenza virus composition for mucous membranes
JPWO2019070019A1 (ja) * 2017-10-05 2020-10-22 東興薬品工業株式会社 経鼻ｂ型肝炎ワクチン組成物およびその製造方法
WO2021002355A1 (ja) 2019-07-03 2021-01-07 アイリス株式会社 インフルエンザウイルス感染症を治療するための医薬組成物
CN113117093B (zh) * 2019-12-31 2024-02-09 辽宁成大生物股份有限公司 一种适用于鼻粘膜递送流感疫苗的促进剂
WO2023120535A1 (ja) * 2021-12-20 2023-06-29 東興薬品工業株式会社 ポリアクリル酸系ポリマーを含有するワクチンアジュバント剤およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5215739A (en) * 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
JPH0678245B2 (ja) * 1989-07-04 1994-10-05 東興薬品工業株式会社 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤
PT1861120T (pt) * 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
TW201414506A (zh) * 2006-04-21 2014-04-16 Toko Yakuhin Kogyo Kk 噴灑用凝膠型皮膚及／或黏膜附著型製劑及使用該製劑之投藥系統
WO2007123207A1 (ja) * 2006-04-21 2007-11-01 Toko Yakuhin Kogyo Kabushiki Kaisha 流体用容器およびこれを用いたエアレス式流体投与システム
WO2010114169A1 (en) 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration

Also Published As

Publication number Publication date
PH12015501482A1 (en) 2015-09-21
DK2939692T3 (da) 2019-07-08
PL2939692T3 (pl) 2019-10-31
AU2013367751A1 (en) 2015-07-09
AU2013367751A8 (en) 2015-08-27
MX371154B (es) 2020-01-20
TW201427724A (zh) 2014-07-16
HUE044434T2 (hu) 2019-10-28
AU2013367751B2 (en) 2018-02-08
IL239284B (en) 2020-02-27
MX2015008380A (es) 2016-03-15
IL239284A0 (en) 2015-07-30
CA2894223C (en) 2021-04-06
RU2015130634A (ru) 2017-02-01
US20160015800A1 (en) 2016-01-21
ES2731899T3 (es) 2019-11-19
CY1122372T1 (el) 2021-01-27
SI2939692T1 (sl) 2019-10-30
BR112015015523A2 (pt) 2017-07-11
EP3566715A1 (en) 2019-11-13
BR112015015523B1 (pt) 2023-02-23
CA2894223A1 (en) 2014-07-03
RU2652296C2 (ru) 2018-04-25
KR102071099B1 (ko) 2020-01-29
JP6247639B2 (ja) 2017-12-13
KR20150102995A (ko) 2015-09-09
NZ708922A (en) 2019-10-25
CN110038123A (zh) 2019-07-23
EP2939692A1 (en) 2015-11-04
EP2939692A4 (en) 2016-07-06
TWI624280B (zh) 2018-05-21
EP2939692B1 (en) 2019-04-24
LT2939692T (lt) 2019-08-12
HK1209646A1 (en) 2016-04-08
US20190091324A1 (en) 2019-03-28
CN104884086A (zh) 2015-09-02
JPWO2014103488A1 (ja) 2017-01-12
MY173503A (en) 2020-01-29
SG10201705190TA (en) 2017-07-28
PT2939692T (pt) 2019-06-27
WO2014103488A1 (ja) 2014-07-03
SG11201504648TA (en) 2015-07-30
PH12015501482B1 (en) 2015-09-21

Similar Documents

Publication Publication Date Title
TR201910293T4 (tr) Nazal influenza aşısı bileşimi.
CY1123434T1 (el) Λυοφιλοποiημενα νανοεναιωρηματα φαρμακων
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2014003308A (es) Vacunas para el virus de la influenza y usos de las mismas.
TR201908596T4 (tr) Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları.
CY1120684T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
WO2012024621A3 (en) Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
TWD163155S (zh) 耳機
MX2015016755A (es) Reagrupamiento del virus de influenza.
ES2681973T3 (es) Respuesta antitumoral contra autoepítopos modificados
EA201590272A1 (ru) Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
NZ606087A (en) Influenza vaccine
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
PH12016502529B1 (en) Influenza vaccine nasal vaccination system
TR201100148A2 (tr) Stabil akarboz förmülasyonları.
EP3083661A4 (en) Cap260, cap174 and k0224 hiv-1 envelopes, peptide and compositions
PH12015502029A1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations
GB201106162D0 (en) Combination vaccine
TR201104977A1 (tr) Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
PH12015502015A1 (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations